Baricitinib（
CAS No.:1187594-09-7） is an Janus kinase inhibitor. It works by blocking the action of the enzyme, Janus kinase. This decreases inflammation and joint damage in rheumatoid arthritis.Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis. Baricitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.
Baricitinib is an orally available, specific inhibitor Janus-associated kinases (mainly JAK1 and JAK2) that is used to treat moderate-to-severe rheumatoid arthritis. The Janus kinases are critical steps in immune activation as well as in hematopoiesis. The immunomodulatory effects of baricitinib have led to its evaluation in several autoimmune conditions including rheumatoid arthritis and psoriasis. In multiple randomized controlled trials, baricitinib was found to improve symptoms and signs of severe rheumatoid arthritis when used alone or in combination with other disease modifying anti-rheumatologic drugs (DMARDs).
